The Provider Locator is compiled and published by Alimera Sciences, Inc. (“Alimera”) as a reference
source of demographic and professional information on individual licensed healthcare providers in
the United States who have experience in the treatment of diabetic macular edema. The Provider
Locator is searchable by state. Healthcare providers' enrollment and participation in the Provider
Locator is voluntary and free of charge and, along with the provider-specific information in the
Provider Locator, is based solely on healthcare provider responses. The Provider Locator is provided
by Alimera for use by the medical community, potential patients and/or their families in order to
find information on, and locate healthcare providers for the treatment of diabetic macular edema.
Alimera is not responsible for, and the Provider Locator is not intended as a tool for, verifying
the credentials, expertise, abilities or quality of care of any healthcare provider included in
the Provider Locator. Inclusion in the Provider Locator does not imply referral, recommendation
or endorsement nor does omission in the Provider Locator imply Alimera disapproval. We recommend
that, before scheduling an appointment to see any healthcare provider, you research the credentials
of the healthcare provider and satisfy yourself that the healthcare provider provides the quality
of care desired. You are prohibited from using, downloading, republishing, selling, duplicating,
or "scraping" for commercial or any other purpose whatsoever, the Provider Locator or any of the
data listings or other information contained therein, in whole or in part, in any medium whatsoever.
The information from the Provider Locator is provided on an "AS-IS" basis. Alimera disclaims all
warranties, either express or implied, including but not limited to the implied warranties of
merchantability and fitness for particular purpose. Without limiting the foregoing, Alimera does
not warrant or represent that the Provider Locator or any part thereof is accurate or complete.
You assume full responsibility for the communications with any healthcare provider you contact
through the Provider Locator. Alimera shall in no event be liable to you or to anyone for any
decision made or action taken by you in the reliance on information.
Important Safety Information
ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg is indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.
Important Safety Information
Do not use ILUVIEN if you have or think you might have an infection in or around the eye.
ILUVIEN should not be used if you have advanced glaucoma.
You should not use ILUVIEN if you are allergic to any ingredients of ILUVIEN.
Injections into the vitreous in the eye are associated with a serious eye infection
(endophthalmitis), eye inflammation, increased eye pressure, glaucoma, and retinal detachments. Your
eye doctor should monitor you regularly after the injection.
Use of corticosteroids including ILUVIEN may produce cataracts (ILUVIEN 82%; sham 50%), increased
eye pressure (ILUVIEN 34%; sham 10%), glaucoma, and may increase secondary eye infections due to
bacteria, fungi, or viruses. Let your doctor know if you have a history of herpes viral infections of
If the posterior capsule of the lens of your eye is missing or torn the ILUVIEN implant may move to
the front chamber of the eye.
The most common side effects reported in patients with diabetic macular edema who were treated with
ILUVIEN include cataracts (ILUVIEN 82%; sham 50%) and increased eye pressure (ILUVIEN 34%; sham 10%).
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.